Gastric Cancer, Gastroesophageal Junction Cancer
Conditions
Brief summary
The purpose of this study is to collect and evaluate real-world data to enhance understanding of the effectiveness, and treatment patterns of first-line nivolumab treatment in patients with unresectable advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) in China
Interventions
DRUGNivolumab
As prescribed by treating physician
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants aged ≥ 18 years at date of first administration of nivolumab * Confirmed diagnosis of unresectable advanced or metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) (histologically or cytologically) * Participants newly received nivolumab as first-line (1L) treatment between 15 June 2018 and 30 June 2023 * Participants with at least one tumor assessment after index date except for death or discontinuation due to Adverse Events
Exclusion criteria
* Participants with primary malignancies other than unresectable advanced or metastatic GC/GEJC * Participants who participate in an interventional clinical trial in or before 1L nivolumab treatment for advanced/metastatic GC/GEJC * Participants with known HER2 status positive * Participants who investigator deems inappropriate for inclusion, for example clinical data was incomplete
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to progression (TTP) | Up to 68 months |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR) | Up to 68 months |
| Duration of response (DOR) | Up to 68 months |
| Participant socio-demographics | Baseline |
| Participant baseline clinical characteristics | Baseline |
| Participant treatment patterns | Up to 68 months |
Countries
China
Outcome results
None listed